Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CVL-231 · 3 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| CVL-231 | DRUG | CVL-231 is a brain penetrant mAChR activator that selectively binds to the M4 mAChR subtype while sparing other muscarinic receptor subtypes (M1, M2, M3, and M5). CVL-231 is being developed for treatment of psychosis in schizophrenia. |
| Matching Placebo | DRUG | Placebo matching CVL-231 |
CVL-231 is an investigational small molecule being developed for schizophrenia and blood pressure. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being studied for its effects on schizophrenia symptoms and on 24-hour ambulatory blood pressure in participants with schizophrenia.
CVL-231 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is conducting clinical trials to evaluate the drug's safety and efficacy in schizophrenia and blood pressure.
CVL-231 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. All completed trials for CVL-231 are Phase 1 studies, including trials in schizophrenia and blood pressure.
CVL-231 has completed three Phase 1 clinical trials. NCT04136873 is a multiple ascending dose trial in schizophrenia with 130 participants. NCT04787302 is a PET trial evaluating target occupancy on brain receptors with 15 participants. NCT05245539 studies the effect on 24-hour ambulatory blood pressure in schizophrenia with 151 participants.
CVL-231 is not known to have alternative names. It is an investigational small molecule developed by AbbVie Inc. for schizophrenia and blood pressure. The drug is currently in Phase 1 clinical trials and has not been approved by regulatory authorities.